Gore Announces First Commercial In-Human Use of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System for TEVAR in Australia

New delivery system provides controlled and predictable placement of Gore’s highly conformable and time-tested stent graft

Jul 24, 2018

FDA Approves GORE® CARDIOFORM Septal Occluder for PFO Closure to Prevent Recurrent Ischemic Stroke

Gore REDUCE Clinical Study demonstrated 77 percent relative reduction in recurrent ischemic stroke when PFO closure was combined with antiplatelet therapy, compared to antiplatelet therapy alone

Apr 3, 2018

First Patient Enrolled in Investigational Study of the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System

Investigating the safety and effectiveness of a stent graft system designed to provide endovascular aneurysm repair (EVAR) with angulation control to patients previously considered untreatable

Jan 3, 2018

First Patients in Europe Treated Following CE Approval for GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis

Dec 22, 2017

Physicians Report Early Successes Across Multiple Applications in First-in-Human Uses of GORE® SYNECOR Preperitoneal Biomaterial Hernia Repair Device

New three-layer hybrid biomaterial, ideal for TAR procedures, offering permanent strength and rapid tissue generation for single-stage repairs

Oct 23, 2017

First Patient Enrolled in European Post-Market Registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System

Real-world outcomes of TEVAR procedures performed with new delivery system that enables positioning and angulation control during stent graft deployment

Oct 20, 2017

Gore Launches Anti-Migration Assurance Program for GORE® VIABIL® Short Wire Biliary Endoprosthesis

Device is proven to reduce the risk of reintervention for patients with pancreatic and other cancers that obstruct the bile duct; replacement program can help limit overall costs of palliative care

Oct 4, 2017

Celebrating the 20th Anniversary of the GORE® EXCLUDER® Device

With two decades of evolution and more than 300,000 patients treated* worldwide, this trusted, market-leading EVAR device continues to advance patient care

Oct 2, 2017

Gore Completes Patient Enrollment in U.S. Pivotal Clinical Study of GORE® CARDIOFORM ASD Occluder

New addition to GORE® CARDIOFORM Occluder family is designed to treat larger atrial septal defects by adapting to the patient’s anatomy for a permanent and safe closure

Sep 26, 2017

GORE® EXCLUDER® Device Reaches Significant Milestone

Proven device for endovascular aneurysm repair (EVAR) reaches 250,000 patients worldwide

Aug 22, 2017